---
title: "CICC Reaffirms Their Buy Rating on Livzon Pharmaceutical Group (LVZPF)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282769048.md"
description: "In a report released on April 13, from CICC maintained a Buy rating on Livzon Pharmaceutical Group, with a price target of HK$39.00. The company’s shares closed last Thursday at HK$28.24.Claim 30% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The word on The Street in general, suggests a Hold analyst consensus rating for Livzon Pharmaceutical Group with a HK$31.01 average price target."
datetime: "2026-04-15T02:03:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282769048.md)
  - [en](https://longbridge.com/en/news/282769048.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282769048.md)
---

# CICC Reaffirms Their Buy Rating on Livzon Pharmaceutical Group (LVZPF)

In a report released on April 13, from CICC maintained a Buy rating on Livzon Pharmaceutical Group, with a price target of HK$39.00. The company’s shares closed last Thursday at HK$28.24.

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The word on The Street in general, suggests a Hold analyst consensus rating for Livzon Pharmaceutical Group with a HK$31.01 average price target.

### Related Stocks

- [01513.HK](https://longbridge.com/en/quote/01513.HK.md)
- [159570.CN](https://longbridge.com/en/quote/159570.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [03908.HK](https://longbridge.com/en/quote/03908.HK.md)
- [601995.CN](https://longbridge.com/en/quote/601995.CN.md)
- [01515.HK](https://longbridge.com/en/quote/01515.HK.md)
- [000513.CN](https://longbridge.com/en/quote/000513.CN.md)

## Related News & Research

- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds](https://longbridge.com/en/news/286487023.md)
- [Goldman Sachs Reaffirms Their Buy Rating on Prudential (PRU)](https://longbridge.com/en/news/286866728.md)
- [Positive Report for Sinotruk Hong Kong (3808) from Bank of America Securities](https://longbridge.com/en/news/286848185.md)
- [Nvidia Will Report Q1 Earnings on May 20 — Options Traders Expect an 8.65% Move in NVDA Stock](https://longbridge.com/en/news/286763191.md)